Molecule AG

We talk a lot about accelerating science in DeSci. But what does this actually look like? DeSci's impact on initial funding for drug discovery is clear, but there is another crucial step in bringing a drug to market: Preclinical Studies. And it's with preclinical studies that DeSci can set a new standard. 🔬 Traditional drug development often takes over a decade, with a lot of effort focused on clinical trials. But we can dramatically speed up the preclinical stage, making it more efficient and sustainable, with DeSci. The current state of preclinical studies: 🔹 Identifying & Validating Targets 🔹 Optimizing Lead Compounds 🔹 Testing Safety & Toxicity 🔹 Studying Pharmacokinetics These crucial steps lay the foundation for drug development, and there is a lot of room for improvement. DeSci is disrupting and accelerating preclinical research by: 🔹 Directing resources to high-impact research 🔹 Making decisions transparent with IP-NFT & IPT governance 🔹 Enhancing collaboration by sharing data 🔹 Accelerating target identification 🔹 Improving reproducibility This transformation brings unprecedented opportunities: For Researchers 🔬 - Unlocks access to funding - Provides faster testing pathways - Reduces early-stage research delays For Institutions 🏛️ - Acts as a risk-mitigation tool for pharma - Offers transparent, capital-efficient funding models - Supports and sustains innovative research For Funders 🤝 - Democratizes access to scientific research - Enables anyone to fund and participate in world-changing research through IPTs DeSci doesn't just improve drug discovery—it transforms it. By building tools to optimize preclinical studies, we're tackling one of the biggest bottlenecks in R&D. Our aim? To bring new treatments to patients faster than ever through collaboration and efficient systems. The future of drug discovery is decentralized, transparent, and lightning-fast. Are you ready to be part of this revolution?

Zelar City comes at Molecule AG DeSci Church! This Sat and Sun we discuss Decentralized Science and Network states! Join us! https://lu.ma/4spe1nm5 Victoria Forest, Laurence Ion, Elias Schlie 🚀🚀🚀  

#DeSci and #NetworkStates Summit Day 1 at DeSci Church with Molecule AG This place is the perfect blend of art and science. The conversations are thought-provoking, and people are curious and open to changing the status quo 🔥 Zelar City has reached its halfway mark! Don’t miss the 3 remaining weekend summits. Check out the weekly themes at https://zelar.city

Over this weekend, there were two amazing Zelar City summits on Decentralized Science (DeSci) and Network States in #longevity 🖥️💉 The talks and workshops of the speakers as well as presented ideas and projects on the impact of decentralized science on rapid research development in medicine were extremely insighful! The implications of novel regulations in healthcare, the emergence of pop-up cities (maybe even countries? Liberland), and the creation of global networks that further collaboration between researchers across the globe—all of these aspirations can help us advance life sciences and foster longevity among a larger public. Thank you so much, Victoria Forest, Laurence Ion, Alexey Strygin, and Elias Schlie, Mark Kagach for being such a fascinating team with whom it is such a pleasure to work 🙌 Also, huge thanks to the whole Molecule AG team for welcoming Zelar City to spread the knowledge about the potential behind #DeSci! Zelar City will continue gathering longevity enthusiasts from all across the world in Berlin for the next 3 weeks! Our next summit will be about Health Optimization and AI: https://lu.ma/omxsp5xu Come and join us in our mission to extend human lifespan!

There's a lot of excitement in crypto around Real-World Assets (RWAs). However, unlike loans and bonds, IP is the ultimate meta-RWA—an asset perfect for tokenization. What are IPTs? Intellectual Property Tokens (IPTs) are fungible governance tokens of an IP-NFT (a tokenized representation of IP). They're transforming how research IP is managed, governed, and monetized—enabling open-source collaboration without losing commercial opportunity. Onchain science is already underway & making incredible strides. And VitaDAO is leading the charge with two remarkable projects combating age-related diseases: VitaFAST: The first-ever IPT funding longevity science 🧪 VitaFAST enables governance of the Viktor Korolchuk Lab IP-NFT, a project focused on discovering novel autophagy enhancers (think "fasting!"). Last year, the VitaDAO community raised over $300,000 to continue the lab's research! VitaRNA: Groundbreaking Gene Therapy 🧬 VitaRNA tokenizes the ARTAN Bio IP-NFT—exploring the promising field of gene therapies that could help address aging-related genetic factors. The VitaDAO community also raised $300,000 to continue Artan Bio's research into their AAV9-based gene therapy. What do IPTs mean for scientific innovation? 🧪 IPTs help accelerate research by aligning incentives around a community of stakeholders that have an opportunity to govern IP and contribute to the research itself. IPTs are the future of scientific innovation, and VitaFAST & VitaRNA are proving just how powerful onchain science is ⛓️🔬 Ready to get involved? 🤝 Connect with the teams: VitaFAST: vitafast.xyz VitaRNA: vitarna.xyz

GM! 🌞 Come co-work with us! Whether you're into DeSci, web3, biotech, or related creative vibes, we're here to connect, collaborate, and create. Can't wait to meet you and your furry friends! 🐶 Fill in the form: https://lnkd.in/d54JAddn

🔬 📰 How many ground breaking scientific reports do you hear every week? Have you ever wondered what goes on in the labs? Want to be involved? What if I told you, you can! For the last 6 months I have been working with Molecule AG for the launch of such a platform! Welcome to Catalyst, a platform where science is brought to the people. Catalyst allows anyone to fund cutting-edge scientific research, giving you an opportunity to change the course of humanity while engaging with scientists on topics YOU care about. Curious how it works? Check out our quick-start guide to learn more! 👉 https://lnkd.in/dqGagU9e 💬 Want to get involved! Join our discord community, where all your answers will be answered! 👉 https://lnkd.in/di3JbEdS

1 in 6 people experience fertility issues in their lifetime. This shouldn't be accepted. Join AthenaDAO & Dr. Mario Cordero's AMA session today, 6pm CET, to learn more about fertility, and what they're doing to fix these looming issues! Set a reminder https://lu.ma/ldci8ecb

We're excited to power AthenaDAO's Intellectual Property Token (IPT) launch today! With 1 in 6 people experiencing fertility issues in their lifetime, Mario Cordero's research into ovarian aging has never been more relevant. You can learn more about the science and token sale over at https://lnkd.in/dukPF5qN

The drug development game needs a new playbook—one that prioritizes innovation over profit. It's time we put researchers back in the driver’s seat. Molecule is handing over the keys—giving researchers control over their research. Welcome to the future of scientific funding 👇 The Current Pharma Playbook: ❌ Prioritizes managing diseases over curing them ❌ Spends 25x more on promoting drugs than discovery ❌ Engages in ever-greening to extend patent protection Meanwhile, our researchers are stuck in grant-writing purgatory, wasting up to 40% of their time on paperwork instead of breakthroughs. That's not innovation—that's bureaucracy. With Molecule's IP-NFTs and IP tokens (IPTs), researchers have a new way to turn intellectual property into an incentive for collaboration and funding. Molecule turns IP into a tradable, shareable asset governed by the people who most benefit from the research. 🔹 No need for early patents or startups to fundraise 🔹 Build a community of supporters 🔹 Keep control over your data and decide who gets access 🔹 Enable anyone to fund and benefit from your research How It Works: IP-NFTs: Own the core IP 🔹 IP can be held by a DAO, project, or researcher 🔹 Tokenized & tradable in liquid markets in the form of IPTs IPTs: Fungible IP 🔹 Governance tokens for an IP-NFT 🔹 They govern IP pools: shared sets of IP and R&D data 🔹 Multiple stakeholders can vote and control IP Why This Matters: 🔹 Enables open-source collaboration without losing commercial opportunity 🔹 Creates an arbitrage in biotech: more equity to patients & researchers = higher quality research at lower cost 🔹 Prioritizes effective cures over corporate profits With IPTs, you’re not just backing research—you’re actively shaping its future. IPTs are enabling a new drug discovery landscape. One with: 🔹 New incentive mechanisms 🔹 Democratized access to innovative research 🔹 Freedom from bureaucracy The future of drug discovery is decentralized. 🌐 And IPTs are just the beginning 🔭 To learn more about the impact of IP-NFTs and IPTs on the future of research funding, read more: https://t.ly/VbvnE